SAN FRANCISCO — OpRegen, a human embryonic stem cell-derived retinal pigment epithelial cell therapy transplanted subretinally, appeared well-tolerated in patients with advanced dry age-related macular degeneration, according to data from an ongoing phase1/2a clinical study presented at the American Academy of Ophthalmology annual meeting.
“The idea is to transplant young, healthy cells to support/replace the failing cells in these patients,” Eyal Banin MD, PhD, director of the degenerative diseases of the retina and macula unit, department of ophthalmology, Hadassah Medical
Uncategorized